{"entity":{"id":"nct04291105","kind":"trial","name":"Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients","aka":[],"tldr":"A phase 2 trial of Cemiplimab in melanoma and head and neck squamous cell carcinoma, run by Vyriad, Inc., active and no longer recruiting.","summary":"Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients is a phase 2 interventional study registered as NCT04291105 by Vyriad, Inc., with 87 participants planned, started 2020-04-24 and due to reach its primary completion in 2026-10. Interventions recorded: VV1, Cemiplimab. Conditions listed: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04291105","url":"https://clinicaltrials.gov/study/NCT04291105"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","head-and-neck","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["cemiplimab"],"companies":["vyriad"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04291105","phase":"2","setting":"Phase 2 Trial of Voyager VI (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination With Cemiplimab in Patients With Select Solid Tumors","sponsor":"Vyriad, Inc.","enrolled":87,"outcomes":[]},"route":"/trials/nct04291105/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"}],"company":[{"id":"vyriad","kind":"company","name":"Vyriad","route":"/companies/vyriad/"}]}}